Annovis Bio reports FY2025 net loss $1.40/sh; Phase 3 AD trial 65% enrolled

Annovis Bio, Inc.

FY2025 net loss $1.40 basic and diluted EPS; R&D $25.2M, G&A $4.5M; cash $19.5M expected to fund into Q3 2026.
Phase 3 AD trial (NCT06709014) 65% enrolled across 83 US sites; DSMB positive recommendation at 6-month safety review.
Open-label extension PD study initiated Jan 2026; FDA positive recommendation for PD dementia study design discussions.
All patents transferred to new crystal form of buntanetap, extending IP protection to 2047.
Appointed Mark Guerin as CFO and Hui Liu as Director of Biostatistics in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Annovis Bio, Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 16, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-028574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.